Gland Pharma to be Acquired by Fosun Pharma
July 28, 2016KKR to Divest its Full Stake
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160728005902/en/
Based on the agreement, Fosun Pharma will purchase all shares of Gland
owned by
KKR invested in Gland in 2014. Since then, the company has seen its capacity and profit grow significantly. This was achieved, in part, by Gland’s investment into a new manufacturing plant, significant optimization of existing facilities, enhanced R&D spend and focus, and Gland’s ability to file for and own further intellectual property.
“We have benefited from the experience of KKR, which brought the skills
and expertise that enabled Gland to grow and develop as a multinational
leader in health care. We achieved improved performance and look forward
to building upon that foundation,”
Following the close of the transaction, Gland will remain headquartered
in
“With a track record of achieving greater scale, innovating world-class
products and operating to global best practices, KKR takes pride in its
relationship with Gland and in The Company’s support of the ‘Make in
India’ campaign. We are confident Fosun Pharma will experience continued
success as it invests and supports Gland’s next stage of growth,” said
Fosun Pharma is a leading researcher, developer, producer and retailer of biopharmaceutical products worldwide.
Mr.
Simpson Thacher &
About Gland
Established in 1978 and based in
About KKR
KKR is a leading global investment firm that manages investments across
multiple asset classes including private equity, energy, infrastructure,
real estate, credit and hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined investment
approach, employing world-class people, and driving growth and value
creation at the asset level. KKR invests its own capital alongside its
partners’ capital and brings opportunities to others through its capital
markets business. References to KKR’s investments may include the
activities of its sponsored funds. For additional information about
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005902/en/
Media
KKR Asia-Pacific
anita.davis@kkr.com
or
KKR Americas
kristi.huller@kkr.com
or
Edelman
(for KKR India)
siddharth.panicker@edelman.com
or
vaishnavi.ramakrishnan@edelman.com
Source:
Back to Press Releases
Media Contacts
Americas
Miles Radcliffe-Trenner
Telephone: +1 (212) 750-8300
Email: media@kkr.com
Investor Relations
Craig Larson
Telephone: +1 (877) 610-4910
Outside US: +1 (212) 230-9410
Facsimile: +1 (212) 750-0003
Email: Investor-Relations@kkr.com